Quick Answer
Ensysce Biosciences, Inc. reported Operating Income Loss of -$10.24 million for the year ending 2025.
- Ensysce Biosciences, Inc. showed a decrease of -52.2% in Operating Income Loss from 2024 to 2025.
- This data is from Ensysce Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: -$5.0 thousand | Q4 2017: -$146.7 thousand | Q1 2018: -$170.1 thousand | Q2 2018: -$311.5 thousand | Q3 2018: -$248.2 thousand | Q1 2019: -$189.2 thousand | Q2 2019: -$625.9 thousand | Q3 2019: -$584.4 thousand | Q1 2020: -$915.2 thousand | Q2 2020: $139.1 thousand | Q3 2020: -$404.8 thousand | Q1 2021: -$524.3 thousand | Q2 2021: -$412.6 thousand | Q3 2021: -$16.89 million | Q1 2022: -$4.80 million | Q2 2022: -$7.06 million | Q3 2022: -$6.16 million | Q1 2023: -$2.56 million | Q2 2023: -$2.29 million | Q3 2023: -$2.71 million | Q1 2024: -$1.84 million | Q2 2024: -$1.96 million | Q3 2024: $644.7 thousand | Q1 2025: -$1.97 million | Q2 2025: -$1.75 million | Q3 2025: -$3.74 million.
- Over the full 8 years of available data (2018 to 2025), Ensysce Biosciences, Inc.'s Operating Income Loss has declined by 967.6%.
- Historical annual values: Fiscal year 2025: -$10.24 million | Fiscal year 2024: -$6.73 million | Fiscal year 2023: -$10.72 million | Fiscal year 2022: -$24.22 million | Fiscal year 2021: -$19.87 million | Fiscal year 2020: -$1.61 million | Fiscal year 2019: -$3.33 million | Fiscal year 2018: -$959.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: